Company

FDA Approves Bayer's Sunharbo (Asundexian) – World's First FXIa Inhibitor for Secondary Stroke Prevention
BayerETR: BAYN

FDA Approves Bayer’s Sunharbo (Asundexian) – World’s First FXIa Inhibitor for Secondary Stroke Prevention

Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for asundexian 50 mg tablets, under the brand name Sunharbo — the first…

Charles River to Acquire Frontage's Bioanalysis and DMPK Operations for ~$470 Million – Expanding Early-Phase Laboratory Footprint in Exton, Pennsylvania

Charles River to Acquire Frontage’s Bioanalysis and DMPK Operations for ~$470 Million – Expanding Early-Phase Laboratory Footprint in Exton, Pennsylvania

Ribo Life Science Files EU Phase I CTA for SR122 – Dual‑Targeting ApoC3/PCSK9 siRNA Advancing Into Europe for Dyslipidemia

Ribo Life Science Files EU Phase I CTA for SR122 – Dual‑Targeting ApoC3/PCSK9 siRNA Advancing Into Europe for Dyslipidemia

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Hengrui's Recaticimab Approved for Hypercholesterolemia Treatment
CVDHengrui Pharmaceuticals

Hengrui’s Recaticimab Approved for Hypercholesterolemia Treatment

HealZen and Johnson & Johnson Partner on BTK Degradation Therapeutics
HealZen TherapeuticsJ&J

HealZen and Johnson & Johnson Partner on BTK Degradation Therapeutics

Hengrui Pharmaceuticals Gets NMPA Approval for SHR-1819 Phase II Study
Auto-immuneClinical trial approval / initiation

Hengrui Pharmaceuticals Gets NMPA Approval for SHR-1819 Phase II Study

Hengrui Pharmaceuticals Receives NMPA Approval for SHR-4375 Clinical Trial
CancerClinical trial approval / initiation

Hengrui Pharmaceuticals Receives NMPA Approval for SHR-4375 Clinical Trial

Show More